

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

Natalizumab for treating highly active relapsing-remitting multiple sclerosis  
ID4020

## Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Biogen (natalizumab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Brain and Spine Foundation</li> <li>• Brain Charity</li> <li>• MS-UK</li> <li>• Multiple Sclerosis Society</li> <li>• Multiple Sclerosis Trust</li> <li>• Neurological Alliance</li> <li>• Shift.ms</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Sue Ryder</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of British Neurologists</li> <li>• British Association of Neuroscience Nurses</li> <li>• British Geriatrics Society</li> <li>• British Neuropathological Society</li> <li>• British Society for Blood and Marrow Transplantation</li> <li>• British Society of Rehabilitation Medicine</li> <li>• Chartered Society of Physiotherapy</li> <li>• Institute of Neurology</li> <li>• London MS-AHSCT Collaborative Group</li> <li>• National Neurosciences Advisory Group</li> <li>• Primary Care and Community Neurology Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• Multiple Sclerosis Society Wales</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• Neurological Alliance of Scotland</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Wales Neurological Alliance</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Glenmark Pharmaceuticals (fingolimod)</li> <li>• Merck Serono (cladribine)</li> <li>• Novartis Pharmaceuticals (fingolimod)</li> <li>• Roche Products (ocrelizumab)</li> <li>• Sanofi Genzyme (alemtuzumab)</li> <li>• Tillomed Laboratories (fingolimod)</li> </ul> <p><u>Research groups</u></p> <ul style="list-style-type: none"> <li>• Brain Research UK</li> <li>• British Neurological Research Trust</li> </ul>

Provisional stakeholder list for the evaluation of natalizumab for treating highly active relapsing-remitting multiple sclerosis ID4020

Issue date: May 2022

## Appendix C

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Royal College of Occupational Therapists</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Therapists in MS</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Multiple Sclerosis Specialist Nurse Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS Castle Point and Rochford CCG</li> <li>• NHS England</li> <li>• NHS North Central London CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group</li> <li>• Cochrane UK</li> <li>• Genomics England</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts, and have the right to appeal against the Final Draft Guidance (FDG).

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.